Renascience, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3981100005
JPY
1,663.00
69 (4.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
RaQualia Pharma, Inc.
Wakamoto Pharmaceutical Co., Ltd.
Solasia Pharma KK
Taiko Pharmaceutical Co., Ltd.
Healios KK
Nippon Chemiphar Co., Ltd.
Fuso Pharmaceutical Industries Ltd.
Renascience, Inc.
BrightPath Biotherapeutics Co., Ltd.
SymBio Pharmaceuticals Ltd.
CanBas Co., Ltd.

Why is Renascience, Inc. ?

1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate 4.82% of over the last 5 years
3
Negative results in Dec 25
  • NET SALES(9M) At JPY 40 MM has Grown at -39.16%
  • NET PROFIT(Q) At JPY -66.59 MM has Fallen at -52.86%
  • DEBT-EQUITY RATIO (HY) Highest at -100.02 %
4
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 38.35%, its profits have risen by 30.7%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Renascience, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Renascience, Inc.
38.35%
3.82
93.85%
Japan Nikkei 225
38.94%
1.30
28.24%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-1.61%
EBIT Growth (5y)
4.82%
EBIT to Interest (avg)
-238.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0.08
Tax Ratio
21.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
13.77
EV to EBIT
-122.43
EV to EBITDA
-122.48
EV to Capital Employed
-274.84
EV to Sales
165.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-10.23%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at JPY -151.44 MM

RAW MATERIAL COST(Y)

Fallen by -21.29% (YoY

-15What is not working for the Company
NET SALES(9M)

At JPY 40 MM has Grown at -39.16%

NET PROFIT(Q)

At JPY -66.59 MM has Fallen at -52.86%

DEBT-EQUITY RATIO (HY)

Highest at -100.02 %

PRE-TAX PROFIT(Q)

Fallen at -35.61%

Here's what is working for Renascience, Inc.

Raw Material Cost
Fallen by -21.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Renascience, Inc.

Net Sales
At JPY 40 MM has Grown at -39.16%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (JPY MM)

Net Profit
At JPY -66.59 MM has Fallen at -52.86%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Pre-Tax Profit
Fallen at -35.61%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Debt-Equity Ratio
Highest at -100.02 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio